Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
CONCLUSION: We developed a clinically relevant signature for patients with chemoresistant TNBC. For these women, new therapeutic strategies like targeting AR activation or cancer stem cells may need to be developed. Clin Cancer Res; 19(10); 2723-33. ©2013 AACR.
PMID: 23549873 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC Tags: Clin Cancer Res Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Stem Cell Therapy | Stem Cells | Women